5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.74▼ | 2.84▼ | 2.87▼ | 2.91▼ | 3.21▼ |
MA10 | 2.84▼ | 2.92▼ | 2.93▼ | 3.16▼ | 3.48▼ |
MA20 | 2.92▼ | 2.97▼ | 3.00▼ | 3.17▼ | 3.58▼ |
MA50 | 2.98▼ | 3.14▼ | 3.21▼ | 3.35▼ | 3.24▼ |
MA100 | 3.06▼ | 3.22▼ | 3.20▼ | 3.58▼ | 3.90▼ |
MA200 | 3.23▼ | 3.25▼ | 3.42▼ | 3.39▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.030▼ | -0.022▼ | -0.022▼ | -0.048▼ | -0.091▼ |
RSI | 35.182▼ | 33.440▼ | 35.583▼ | 37.913▼ | 43.828▼ |
STOCH | 8.507▼ | 15.989▼ | 23.832 | 21.207 | 22.279 |
WILL %R | -95.890▼ | -96.203▼ | -96.970▼ | -98.759▼ | -99.381▼ |
CCI | -127.358▼ | -207.407▼ | -247.719▼ | -161.644▼ | -97.493 |
Thursday, June 05, 2025 04:59 PM
June 06, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene ...
|
Thursday, May 01, 2025 05:00 PM
The latest price target for Senti Biosciences (NASDAQ:SNTI) was reported by Chardan Capital on May 2, 2025. The analyst firm set a price target for $12.00 expecting SNTI to rise to within 12 ...
|
Wednesday, April 16, 2025 06:15 AM
Morningstar brands and products Company Portfolio ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
13/06/25 | 2.91 | 2.95 | 2.675 | 2.69 | 71,616 |
12/06/25 | 3.035 | 3.0958 | 2.7863 | 2.86 | 102,778 |
11/06/25 | 3.20 | 3.20 | 2.78 | 2.81 | 183,797 |
10/06/25 | 3.11 | 3.33 | 3.045 | 3.05 | 124,517 |
09/06/25 | 3.65 | 3.70 | 2.99 | 3.12 | 287,663 |
06/06/25 | 3.57 | 3.884 | 3.30 | 3.84 | 67,600 |
05/06/25 | 3.247 | 3.62 | 3.24 | 3.56 | 24,000 |
04/06/25 | 3.2007 | 3.43 | 3.07 | 3.39 | 27,060 |
03/06/25 | 3.18 | 3.2091 | 3.04 | 3.15 | 20,345 |
02/06/25 | 3.15 | 3.25 | 3.09 | 3.09 | 13,800 |
|
|
||||
|
|
||||
|
|